Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
10 Enero 2025 - 7:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES Exchange ACT OF 1934
For
the month of December 2024
Commission File Number 001-39124
Centogene
N.V.
(Translation of registrant's name into English)
Am Strande
7
18055 Rostock
Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Centogene N.V.
Management Board Matters
On December 24, 2024, Peter Bauer, M.D. notified
the Supervisory Board (the “Supervisory Board”) of Centogene N.V. (the “Company”) of his resignation from his
position as a member of the Management Board, effective as of June 30, 2025. Such resignation was not the result of any dispute with
the Company or the Management Board on any matter relating to the operations, policies or practices of the Company.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date:
January 10, 2025
|
CENTOGENE N.V. |
|
|
|
By: |
/s/ Peter Bauer |
|
|
Name: |
Peter Bauer |
|
| Title: | Chief Medical and Genomic Officer |
Centogene NV (QB) (USOTC:CNTGF)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Centogene NV (QB) (USOTC:CNTGF)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
Real-Time news about Centogene NV (QB) (OTCMarkets): 0 recent articles
Más de Centogene NV (QB) Artículos de Noticias